Komori
Daito Pharmaceutical (4577) · RiskMaterialised

Risks from differences in overseas business environments and regulations

First written in FY2016. 2 of 4 entries say "Restated". Latest entry: FY2025-H1.

4entries
10years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY20182016: 120162017: 120172018: 120182019: 020192020: 020202021: 020212022: 020222023: 020232024: 020242025: 1
Same theme, other companies
Risks Relating to Laws and Regulations and Political and Economic Conditions in Overseas MarketsA theme 446 companies write about · 452 as a headwind · 0 as a tailwind

Daito Pharmaceutical moved to the "Worse" side of this theme in 2025, 4 years after the typical company in this theme (2021).

The whole theme swung hardest in 2025: 47 of 94 companies on the "Worse" side.

27 other companies' latest entry also says "Materialised".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 197 companies compared. The sentences above are computed from all 197.Comparing 200 of the theme's 452 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2025-H1MaterialisedAnnual report

    「Ogito Pharmaceutical (China) Co., Ltd., a consolidated subsidiary of the Company, received an assessment from the Chinese tax authorities concerning transfer pricing rules and other matters in connection with its transactions with the Company, and recorded the ¥388 million paid as corporate income taxes for prior periods in the current interim consolidated accounting period.」

    In connection with the risk of differences in overseas laws, regulations and administrative practices, the company describes an assessment by the Chinese tax authorities concerning transfer pricing rules and other matters and the payment of ¥388 million.
  2. FY2018RestatedAnnual report

    「The Group is expanding its business operations overseas, including in China and the United States. Because business environments overseas differ, including in terms of laws and regulations and the nature of administrative guidance, the Group’s operating results and other aspects of its performance may be affected by unexpected costs and other factors.」

    The risk of differences in laws, regulations and administrative practices in overseas operations, including in China and the United States, continues to be disclosed.
  3. FY2017RestatedAnnual report

    「Because business environments overseas differ, including in terms of laws and regulations and the nature of administrative guidance, the Group’s operating results and other aspects of its performance may be affected by unexpected costs and other factors.」

    The risk of differences in laws, regulations and administrative practices in overseas operations, including in China and the United States, continues to be disclosed.
  4. FY2016First statedAnnual report

    「Because business environments overseas differ, including in terms of laws and regulations and the nature of administrative guidance, the Group’s operating results and other aspects of its performance may be affected by unexpected costs and other factors.」

    Differences in institutions and administrative practices associated with business operations in China, the United States and elsewhere are identified as a risk.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Daito Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risks from differences in overseas business environments and regulations | Daito Pharmaceutical Co.,Ltd. (4577) | Komori